tbuckley/cabot-search huggingface dataset:
Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)
Authors: Thomas Relander, Grete Fossum Lauritzsen, Esa Jantunen, Hans Hagberg, Harald Anderson, Eva Cavallin-Ståhl, Harald Holte, Anders Østerborg, Mats Merup, Peter De Nully Brown, Bj∅rn Østenstad, Outi Kuittinen, Martin Erlanson, Unn-Merete Fagerli, Ole Gadeberg, Christer Sundstrom, Jan Delabie, Elisabeth Ralfkiaer, Martine Vornanen, Francesco d’Amore
Journal: Blood (2010)
Flow Cytometric Detection of Minimal Residual Disease One Year Post Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with B-CLL.
Authors: Uta Oelschlaegel, Martin Bornhäuser, Alexander Kiani, Uwe Platzbecker, Christoph Röllig, Martin Wermke, Christian Thiede, Gerhard Ehninger, Johannes Schetelig
Journal: Blood (2009)
Age-Related Influence on the Clinical Course of Hereditary Angioedema Due to C1- Inhibitor Deficiency (HAE-C1-INH) – a Retrospective Study in 150 Adult Patients
Authors: Inmaculada Martinez-Saguer, Carmen Escuriola-Ettingshausen, Zeynep Gutowski, Richard Linde
Journal: Journal of Allergy and Clinical Immunology (2017)
Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation
Authors: Claudio G Brunstein, Corey S Cutler, Todd E. DeFor, Thomas R. Spitzer, Nelli Bejanyan, Alfred L. Garfall, Michael R. Verneris, Yi-Bin Chen, Erica Warlick, Haesook T. Kim, Jeffrey S. Miller, Joseph H. Antin, Daniel J. Weisdorf, Robert J Soiffer, John E Wagner, Karen K. Ballen
Journal: Blood (2015)
Epidemiology of Multiple Myeloma in Spain: An Analytic Review.
Authors: A. Alegre, F. Lara, R. Gabriel, B. Aguado, L.M. Sánchez, S. Damiano, J. San Miguel, J. Blade, J.J. Lahuerta, A. Sureda, J. García-Laraña, J. Díaz Mediavilla, F. de Arriba, J. de la Rubia, F. Prosper, J. Bargay, R. Martínez, C. Martinez-Chamorro, M.T. Hernández, F. Hernández-Navarro, J. Besalduch, M. González-López, J. Petit, C. Solano, L. Hernández-Nieto, J. Baro, R. Parody, R. Cabrera, E. Flores, M.T. Bernal, J.F. Tomás, J.M. Fernández-Rañada
Journal: Blood (2005)
Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Authors: Max S. Topp, Nicola Goekbuget, Gerhard Zugmaier, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz A. Horst, Albrecht Reichle, Reinhard Marks, Christoph Faul, Monika Brueggemann, Matthias Ritgen, Petra Klappers, Noemi Mergen, Marie-Elisabeth Goebeler, Hermann Einsele, Ralf Bargou
Journal: Blood (2012)
Endothelial glycocalyx breakdown is mediated by angiopoietin-2
Authors: Alexander Lukasz, Carina Hillgruber, Hans Oberleithner, Kristina Kusche-Vihrog, Hermann Pavenstädt, Alexandros Rovas, Bettina Hesse, Tobias Goerge, Philipp Kümpers
Journal: Cardiovascular Research (2017)

The endothelial glycocalyx (eGC), a carbohydrate-rich layer lining the luminal surface of the endothelium, provides a first vasoprotective barrier against vascular leakage and adhesion in sepsis and vessel inflammation. Angiopoietin-2 (Angpt-2), an antagonist of the endothelium-stabilizing receptor Tie2 secreted by endothelial cells, promotes vascular permeability through cellular contraction and junctional disintegration. We hypothesized that Angpt-2 might also mediate the breakdown of the eGC. Using confocal and atomic force microscopy, we show that exogenous Angpt-2 induces a rapid loss of the eGC in endothelial cells in vitro. Glycocalyx deterioration involves the specific loss of its main constituent heparan sulphate, paralleled by the secretion of the heparan sulphate-specific heparanase from late endosomal/lysosomal stores. Corresponding in vivo experiments revealed that exogenous Angpt-2 leads to heparanase-dependent eGC breakdown, which contributes to plasma leakage and leukocyte recruitment in vivo. Our data indicate that eGC breakdown is mediated by Angpt-2 in a non-redundant manner.
Impact of ERG3 mutations and expression of ergosterol genes controlled by UPC2 and NDT80 in Candida parapsilosis azole resistance
Authors: J. Branco, M. Ola, R.M. Silva, E. Fonseca, N.C. Gomes, C. Martins-Cruz, A.P. Silva, A. Silva-Dias, C. Pina-Vaz, C. Erraught, L. Brennan, A.G. Rodrigues, G. Butler, I.M. Miranda
Journal: Clinical Microbiology and Infection (2017)
Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402)
Authors: S. Yuki, Y. Komatsu, H. Satake, Y. Miyamoto, H. Tanioka, A. Tsuji, M. Asayama, T. Shiraishi, M. Kotaka, A. Makiyama, T. Kashiwada, N. Takeuchi, M. Shimokawa, H. Saeki, E. Oki, Y. Emi, H. Baba, Y. Maehara
Journal: Annals of Oncology (2016)
Risk model for clinically relevant neutropenic event among patients with non hematological tumors receiving chemotherapy regimens not classified as high-risk for febrile neutropenia: results from a multicenter prospective cohort study (NEURISK)
Authors: J. Muñoz-Langa, P. Borrega, J.M. García-Bueno, P. Purificación Martínez del Prado, J.M. Campos, M. Quindos, R. López Castro, V. Valentí Moreno, E. Jiménez Orozco, M. Lazaro
Journal: Annals of Oncology (2016)
Prospective analysis of CEA, CA19.9, circulating DNA (cDNA) and circulating tumor cells (CTC) in patients (pts) treated for a metastatic colorectal cancer (mCRC)_Results of COCA-COLON study
Authors: D. Sefrioui, N. Vasseur, E. Toure, F. Blanchard, J. Delacour, C. Thill, L. Beaussire, A. Gillibert, F. Ziegler, A. Gangloff, K. Bouhier-Leporrier, A.-C. Lefebvre, A. Parzy, M.-P. Gallais, F. Clatot, A. Perdrix, J.-C. Sabourin, T. Frebourg, P. Michel, F. Di Fiore
Journal: Annals of Oncology (2016)
Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection
Authors: S. Sanges, F. Wallet, N. Blondiaux, D. Theis, I. Vérin, A. Vachée, R. Dessein, K. Faure, N. Viget, E. Senneville, O. Leroy, F. Maury, N. Just, J. Poissy, D. Mathieu, A. Prévotat, C. Chenivesse, A. Scherpereel, G. Smith, B. Lopez, J. Rosain, V. Frémeaux-Bacchi, E. Hachulla, P.-Y. Hatron, M. Bahuaud, F. Batteux, D. Launay, M. Labalette, G. Lefèvre
Journal: Clinical Microbiology and Infection (2017)
Hemolysis-Associated Elevation in Tricuspid Regurgitation Velocity Predicts Reduction in Six-Minute Walk Distance After Two Years of Follow up in Children and Adolescents with Sickle Cell Disease.
Authors: Victor R. Gordeuk, Lori Luchtman-Jones, Andrew D. Campbell, Sohail R Rana, Mehdi Nouraie, Craig Sable, Niti Dham, Gregory Ensing, Caterina Minniti, Gregory J Kato, Mark Gladwin, Oswaldo L Castro
Journal: Blood (2009)
Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis.
Authors: Catherine Thieblemont, Remi Houlgatte, Pascale Felman, Alexandra Traverse-glehen, Lucile Baseggio, Delphine Rolland, Evelyne Callet-Bauchu, Gilles Salles, Francoise Berger, Bertrand Coiffier
Journal: Blood (2008)
Evolution of multidisciplinary care: Experience of the National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP).
Authors: Eliot Lawrence Friedman, Paul Morris, Margaret Currens, Kathleen M. Castro, Steven B. Clauser, Irene Prabhu Das, Angela Carrigan, Silvana Rivero
Journal: Journal of Clinical Oncology (2012)

67 Background: A key aim of the NCCCP is to develop and improve the quality of multidisciplinary care (MDC). An assessment tool with nine key elements relevant to MDC structure and operations was developed to assess MDC maturity and set goals for continued quality improvement at individual sites and across the network. Methods: 14 NCCCP sites self-reported MDC assessments for lung, breast, and colorectal cancer in June 2010, 2011, and 2012 using an online reporting tool. Each site evaluated their level of maturity (level 1 = no MDC, level 5 = highly integrated MDC) in nine elements integral to the MDC process. Qualitative review of sites’ responses was also conducted. Results: MDC improvement was most evident in four of nine elements; case planning (CP), physician engagement (PE), integration of care coordination (ICC), and quality improvement (QI). The number of sites at level 3 or greater is reported in the table below. Integration of primary care providers and increased organizational support contributed to improved CP. PE was related to conditions of participation, insuring involvement of appropriate physicians in the MDC. The network focus on patient navigation was demonstrated by increase of ICC. Improvement in QI was related to increased participation of sites in physician and hospital quality initiatives (i.e., QOPI and RQRS), and an NCCCP project aimed at increasing referrals to genetics for patient with breast and colon cancer. Conclusions: The maturity of MDC reflected focused work of the Quality of Care sub-committee of the NCCCP. The efforts of working groups in patient navigation, genetics and physician conditions of participation was made evident in the improved performance in MDC’s for three of the four most common malignancies seen in the United States. We hope that this work will provide a blueprint for other health systems that wish to incorporate multidisciplinary care into their cancer programs. [Table: see text]
Effect of a combination of aurora kinase A inhibitor MLN-8237 and cisplatin on gastrointestinal tumors.
Authors: Vikas Sehdev, Mohammed Soutto, Abbes Belkhiri, Jeffrey Ecsedy, Wael El-Rifai
Journal: Journal of Clinical Oncology (2012)

58 Background: Gastric cancers respond poorly to current chemotherapeutic protocols indicating active intrinsic mechanisms against drug induced cell death. We have previously reported that AURKA overexpression induces pro-survival (AKT and β-catenin) and inhibits apoptotic (p53 and p73) pathways. Methods: We evaluated the effect of AURKA specific inhibitor (MLN-8237) alone and/or in combination with cisplatin (CDDP) in gastrointestinal (GI) cancer cells. Following treatment with MLN-8237 and/or CDDP, cell survival, cell viability, western blot and qRT-PCR analyses were done on GI cancer cell lines. Additionally, tumor xenografted mice were treated with MLN (30mg/kg) and/or CDDP (2mg/kg) for 21 days and tumor volume was measured every alternate day. Results: The ATP-Glo cell viability and cell survival assay data indicated that in comparison to single agent treatments alone; the combination treatment with MLN-8237 (0.5µM) and CDDP (2.5µM) significantly increased inhibition of cellular viability and survival (p&lt;0.05) in AGS, KATO-III, MKN28, FLO-1, OE-19 and OE33 cell lines. Similarly, the western blot data exhibited higher levels of p73, Puma, Noxa, cleaved caspase 3 and cleaved PARP with MLN (0.5µM) and CDDP (2.5µM) combination treatment, as compared to single agent treatments in AGS, FLO-1 and OE33 cell lines. The tumor growth results for OE33 mouse xenograft study demonstrate synergistic antitumor effect with MLN-8237 and CDDP combination in the following order of effectiveness: Control &gt; CDDP &gt; MLN-8237 &gt; and MLN-8237/CDDP (p&lt;0.01). Moreover, the qRT-PCR data from tumor xenograft samples treated with MLN-8237/CDDP combination showed significantly higher mRNA levels of p73 downstream transcriptional target genes (P21, PUMA, NOXA and BAX) (p&lt;0.05). Conclusions: Our in vitro and in vivo data indicate that inhibition of AURKA with MLN-8237 in combination with CDDP enhances the antitumor activity of MLN-8237 against GI cancer cells. Therefore, our study demonstrates that MLN-8237 is an effective anti-tumor agent which can be potentially combined with CDDP for better therapeutic outcome in GI cancer patients.
Management optimization of non small cell lung cancer (NSCLC) specimens. A single institution experience with a multiplexed mass spectrometry approach
Authors: G. De Maglio, A. De Pellegrin, A. Follador, S. Distefano, G. Morana, P. Vailati, N. Bergamin, S. Ciani, E. Poletto, E. De Carlo, G. Pelizzari, M. Cattaneo, E. Lugatti, G. Fasola, S. Pizzolitto
Journal: Annals of Oncology (2016)
A Large Cluster of Micrornas At 14q32 Defines an RNA Expression Module That Accounts for Racial Differences in Protease Activated Receptor 4-Mediated Platelet Reactivity
Authors: Leonard C. Edelstein, Lukas M. Simon, Edward Chen, Angela Bergeron, Xiango Kong, Lin Ma, Raul Teruel-Montoya, Michael Holinstat, Srikanth Nagalla, Jing-fei Dong, Chad Shaw, Paul F. Bray
Journal: Blood (2012)
Correction of Anemia with Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), in Oncology Patients Receiving Chemotherapy.
Authors: Lisa M. Pickering, Karel Cwiertka, Jacek Jassem, Jira Petera, Ruth Pettengell, Rodryg Ramlau, Jiri Vorlicek, Rostislav Vyzula, Anne-Marie Duliege, William Lang, Richard B. Stead, Peter G. Harper
Journal: Blood (2007)
307PD Results of high dose rate interstitial- brachytherapy in the treatment of locally advanced carcinoma cervix: A single institution experience
Authors: S.D. Shamsundar, K. Aradhana, R. Nanda, B. Thejaswini, G.V. Giri, A.S. Udaykrishna, H.B. Govardhan
Journal: Annals of Oncology (2016)
Junior doctor dispute may have lasting impact on NHS, researchers say
Authors: Matthew Limb
Journal: BMJ (2017)

The dispute over the contract for junior doctors in England may have a long lasting effect on the NHS because it led many junior doctors to change specialties or defer training, researchers have said.

A survey of junior doctors’ career intentions found that many changed their career plans during the dispute. A report on the findings concluded that decisions made “in the heat of a turbulent time” could turn out to have “significant consequences.”1

Among those applying to train in general practice, 30% said that they had switched choice because of the new contract. In addition, those applying for acute care hospital programmes were significantly more likely to defer training than those applying for community care posts.

The …
Imatinib Mesylate Disrupts Cell Cycle Progression, Modifies the Nucleoskeleton and Suppresses Activation-Induced Transcription in Human T Cells.
Authors: Allan Dietz, William B. Johnson, Gaylord J. Knutson, Peggy A. Bulur, Bertie Schulenberg, Joe M. Beechem, Franklyn G. Prendergast, Stanimir Vuk-Pavlovic
Journal: Blood (2004)
125P Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab
Authors: C. Veenstra, S. Ellegard, G. Perez-Tenorio, V. FagerstrOm, J. Garsjo, K. Briedis, M. Sundqvist, A. MalmstrOm, S. Wingren, O. Stai
Journal: Annals of Oncology (2016)
Epoetin Alfa Biosimilar Treatment for Chemotherapy-Induced Anemia in Current Oncology and Hematology Practice: An Iron Supplementation Subanalysis of the Synergy Study
Authors: Florian Scotté, Kamel Laribi, Christian Gisselbrecht, Dominique Spaeth, Emna Kasdaghli, Hélène Albrand, Eric Leutenegger, Isabelle Ray-Coquard
Journal: Blood (2015)
Impact of Conditionning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children with Acute Myeloid Leukemia in First Complete Remission: Total-Body Irradiation and Cyclophosphamide Versus Busulfan and Cyclophosphamide - A Report from The Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
Authors: Jean-Hugues Dalle, Luc Caty, Regis Peffault, Alexandra Salmon, Valerie Mialou, Claire Galambrun, Karima Yakouben, Francoise Mechinaud, Pierre Bordigoni
Journal: Blood (2007)
Neutrophil-to-lymphocyte ratio as a biomarker for prognosis in localized colorectal carcinoma
Authors: N. Chic, G. Bruixola, O. Reig, R. Diaz- Beveridge, E. Buxo, E. Pineda, A. Prat, J. Aparicio, J. Maurel
Journal: Annals of Oncology (2016)
Disseminated Adenovirus Infections after Allogeneic Hematopoietic Stem Cell Transplantation: High Rate of Associated Co-Morbidity and Mortality.
Authors: Marie Robin, Stéphanie Marque-Juillet, Catherine Scieux, Régis Peffault de Latour, Christèle Ferry, Vanderson Rocha, Agnès Devergie, Eliane Gluckman, Patricia Ribaud, Gérard Socié
Journal: Blood (2006)
522O_PR Analgesia for cancer pain in Southeast Asia (SEA): Prescription patterns, pain control, treatment satisfaction and quality of life (QoL)
Authors: F.O. Javier, D.H.Q. Thinh, W. Sriraj, M.B. Mansor, C. Irawan, S.B. Yusak, J. Kurnianda, Y.P. Nguyen, A. Ong-Cornel, Y. Hadjiat, H. Moon
Journal: Annals of Oncology (2016)
Autologous Stem Cell Transplantation Followed By Allogeneic SCT Provides Promising Results in Patients with Relapsed DLBCL and Adverse Prognostic Features Compared with ASCT Alone
Authors: Roberto Crocchiolo, Barbara Sarina, Stefania Bramanti, Lucio Morabito, Andrea Rimondo, Monica Balzarotti, Massimo Magagnoli, Carmelo Carlo-Stella, Armando Santoro, Luca Castagna
Journal: Blood (2015)
Awareness of predictors of mortality may help improve outcome in chronic pulmonary aspergillosis
Authors: Helmut J.F. Salzer, Oliver A. Cornely
Journal: European Respiratory Journal (2017)

Chronic pulmonary aspergillosis (CPA) is a severe fungal infection usually seen in immunocompetent patients with underlying respiratory disorders [1]. Estimates suggest that ∼3 million people suffer from CPA globally [2]. The precise prevalence is unknown. Pulmonary tuberculosis (TB) seems to be the most relevant driver for the global burden of CPA with estimates suggesting about 1.2 million patients with CPA as a sequel to TB [3]. Given that there were 10.4 million new TB cases in 2015, CPA represents a serious sequela to pulmonary TB [4]. However, any search for CPA in the Global Tuberculosis Report of the World Health Organization (WHO) is still in vain [4]. The relative frequency of CPA after standard antituberculous treatment is estimated to be 17% after 12 months and increases to 22% after 48 months. This data, however, is based on two historic UK studies from 1968 and 1970 in which fungal evidence was confirmed by Aspergillus precipitins (59% sensitivity, 100% specificity) and radiological features considered only aspergilloma [3, 5, 6]. Thus, the frequency of CPA might even be higher, when using Aspergillus -specific IgG antibody assays, which are superior to Aspergillus precipitins with a sensitivity of up to 96% and a specificity of 98%, and when radiological criteria consider all CPA entities, especially chronic cavitary pulmonary aspergillosis (CCPA) [7]. Follow-up visits of TB patients, especially those with cavitary TB, should always include a diagnostic work-up for CPA. Whether CPA plays even a larger role in multidrug-resistant (MDR) and extensively drug-resistant (XDR)-TB patients is entirely unknown. MDR/XDR-TB patients experience a more progressive destruction of the lung and global rates of MDR/XDR-TB are increasing considerably [4, 8]. Predictors of mortality in chronic pulmonary aspergillosis <http://ow.ly/CUyT307S4LL>
PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma
Authors: Paul G. Richardson, Melissa Alsina, Donna Weber, Steven E. Coutre, Sagar Lonial, Cristina Gasparetto, Sutapa Mukhopadhyay, Michael Ondovik, Mahmudul Khan, Carole Paley, Robert Schlossman
Journal: Blood (2012)
Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants
Authors: Paola Bianchi, Elisa Fermo, Kimberly Lezon-Geyda, Patrick G. Gallagher, D Holmes Morton, Wilma Barcellini, Bertil Glader, Stefan W. Eber, Jenny M. Despotovic, Christine M. Knoll, Hassan M. Yaish, Peter E. Newburger, Jennifer Rothman, Alexis A. Thompson, Yaddanapudi Ravindranath, Kerri A Nottage, Heng Wang, Eduard J. van Beers, Joachim Kunz, Marcin W Wlodarski, Mukta Sharma, Melissa J. Rose, Yves D. Pastore, Patricia J. Giardina, Melissa Rhodes, Kevin Kuo, Dongjing Guo, Wendy B. London, Rachael F. Grace
Journal: Blood (2015)
Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies
Authors: C.I. Diakos, D. Tu, V. Gebski, S. Yip, K. Wilson, C.S. Karapetis, C.J. O'Callaghan, J. Shapiro, N. Tebbutt, D.J. Jonker, L.L. Siu, R. Wong, C. Doyle, A.H. Strickland, T.J. Price, J. Simes, S. Clarke
Journal: Annals of Oncology (2016)
GENT-39. A UNIFIED DIAGNOSTIC PLATFORM FOR MALIGNANT GLIOMAS TO ASSESS RADIATION RESPONSE, TCGA SUBCLASS, COPY NUMBER ALTERATION (CNA), G-CIMP STATUS, AND MGMT PROMOTER HYPERMETHYLATION
Authors: Jie Yang, Qianghu Wang, Lihong Long, Ravesanker Ezhilarasan, Adriana Olar, Erik Sulman
Journal: Neuro-Oncology (2016)

Prognostic and predictive molecular diagnostics for patients with gliomas typically rely on multiple assays, requiring large amounts of tissue and high cost. DNA methylation has been utilized to identify prognostic subsets and high-throughput platforms exist that are suitable for archival tissue. We sought to develop a single diagnostic assay based on the Illumina Infinium MethylationEpic BeadChip array to assess multiple prognostic and predictive biomarkers. WHO grade II-IV gliomas were analyzed in both publically available and institutional datasets. Biomarkers assay included a glioma methylation assay that predicts radiation response (GaMA) derived from glioma stem-like cell analysis; tumor classification enriched for TCGA expression subclasses; copy number alternations including phosphatase and tensin Homolog (PTEN) loss, epidermal growth factor receptor (EGFR) amplification, and chromosomes 1p/19q co-deletion; CpG island methylation phenotype (G-CIMP); and O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation. Array intensity files were extracted and normalized and subclass determined by single sample gene set enrichment analysis (ssGSEA). CNA was determined using deferential probe intensity with a preconfigured segmentation algorithm. MGMT methylation was determined using a gradient boosted decision tree algorithm. GaMA discriminated 272 patients who received radiation therapy (RT) into RT-sensitive and RT-resistant subgroup. Survival analysis showed that median survival time for RT-sensitive patients are 21.0 month while 14.7 months for RT-resistant patients (Log rank test p-value=0.0016). 315 cases with gene expression and DNA methylation data were analyzed for TCGA subclass recapture. The predicted subtypes’ accuracy was 0.82 compared to known TCGA subtype. IDH1 mutation and G-CIMP prediction signatures identified 99% of the samples. Among 208 cases with matched methylation specific PCR data, Epic-based MGMT methylation prediction accuracy was 92%, a significant improvement over other published methods based on this platform (MGMT-STP27). In summary, we have developed a single, FFPE-based assay for unified determination of multiple biomarkers of malignant glioma.
Next Generation RNA Sequencing of Acute Promyelocytic Leukemia (APL) Identifies Novel Long Non Coding RNAs Including New Variants of MIR181A1HG That Are Differentially Expressed during Myeloid Differentiation
Authors: Frederic Lammer, Marion Klaumuenzer, Maximilian Mossner, Johann Christoph Jann, Anna Hecht, Verena Nowak, Stephanie Fey, Julia Oblaender, Jovita Pressler, Eva Lengfelder, Wolf-Karsten Hofmann, Daniel Nowak
Journal: Blood (2014)
Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL): Fatty Acid Synthase (FASN) and PI3K Dependent Cell Death Identifies a Novel Therapeutic Paradigm
Authors: Ravi Dashnamoorthy, Afshin Beheshti, Nassera Abermil, Frederick Lansigan, William Kinlaw, Ron Gartenhaus, Graham Jones, Lynn Hlatky, Andrew M. Evens
Journal: Blood (2015)
Clinical Outcomes of Patients with Primary Myelofibrosis in Japan: A Nationwide Survey over a 17-Year Study Period
Authors: Katsuto Takenaka, Kazuya Shimoda, Naoyuki Uchida, Taizo Shimomura, Koji Nagafuji, Tadakazu Kondo, Hirohiko Shibayama, Takehiko Mori, Kensuke Usuki, Taichi Azuma, Yutaka Tsutsumi, Junji Tanaka, Hitomi Dairaku, Keitaro Matsuo, Keiya Ozawa, Mineo Kurokawa, Shunya Arai, Koichi Akashi
Journal: Blood (2016)